Yuwen Liu 刘毓文
Founding Partner of BOHE Angel Fund, a 200M RMB fund jointly invested by Wuxi Apptec, Hengrui, Simcere, TigerMed and BGI,etc. This is the first angel fund focusing on healthcare technology-driven start-ups in China, with Xiaodong Wang and Yigong Shi sitting on its scientific advisory board. It has invested into XinKangHe biological, Transcriptic, SmartNuclide, Athelas Therapeutics, CoolLing Biotech, and HighField BioPharmaceutical covering drug discovery, diagnostic and innovative service solutions.
Before she sets up this fund, she was Chairwoman & CEO then executive director of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY) for 9 years, when she was also Investment Committee Member for BioVENTURE Fund, and Board Director of Innovent, Admera Health, Chiral Quest, GenePharma, Reproposing and BrightGene, and Chairwoman of Qiagen (Suzhou) Translational Medicine and Suzhou BioTOP Biotech. She joined the company as EVP in 2005, was instrumental in building BioBAY to be one of the fastest growing biotech clusters serving ~400 biotech startup companies.
She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager. In 2003, she joined Perrigo as first Chief Representative to set up its China operation
She graduated from China Pharmaceutical University with master degree in Pharmaceutics and Master of Management at Fudan University and Norwegian Management School BI. She is a licensed pharmacist.
刘毓文
薄荷天使基金创始合伙人
薄荷天使基金是一支2亿人民币、专注投资和孵化医疗健康初创期技术型企业的早期基金，出资人包括药明康德、恒瑞医药、先声药业、泰格医药、华大基因、飞翔集团和远翼基金等。薄荷天使基金已投项目包括鑫康合、Transcriptic、智核生物、Athelas Therapeutics、酷瓴生物、高田生物等初创期研发企业。
在创办这支基金之前，她曾于2005-2015年担任苏州工业园区生物产业发展有限公司(BioBAY、生物纳米园) 常务副总经理、总经理、董事长兼总经理和执行董事，帮助将苏州生物纳米园打造为有四百余家生物医药创业企业集聚的中国最具活力生物创新园区之一。
同时她还曾担任信达生物、吉玛基因、凯瑞斯德、瑞璞鑫、博瑞生物、Admera等公司董事，元生创投投决会委员，凯杰（苏州）转化医学公司董事长、齐云创智工坊董事长、百拓生物技术有限公司董事长。
她的职业生涯从1997年加入苏州胶囊有限公司担任质量工程师开始，后陆续担任过质量控制经理、质量保证与控制经理、新业务拓展经理，后于2003年移至上海担任美国百利高国际公司首任中国代表。
她于1990~1997 年就学于中国药科大学获药剂学硕士，后获得复旦大学与挪威管理学院合办之管理学硕士，并是一名执业药师。